Hostname: page-component-7b7567c8c-7pwfn Total loading time: 0 Render date: 2026-11-14T06:19:36.155Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment of Obsessive-Compulsive Disorder

Published online by Cambridge University Press:  07 November 2014

Stuart A. Montgomery
Get accessRights & Permissions [Opens in a new window]

Abstract

All the research to date implicates serotonin as the major neurotransmitter involved in obsessive-compulsive disorder (OCD). Much of the evidence has come from clinical treatment studies, which have shown the specific antiobsessional effect of drugs that are potent inhibitors of serotonin reuptake. Only the selective serotonin reuptake inhibitors (SSRIs) and the potent inhibitors of serotonin reuptake have been shown to be effective in treating patients with OCD. Serotonin receptor inhibitors and SSRIs have been thoroughly investigated in short- and long-term placebo-controlled studies and all have been found to be effective in OCD.

Information

Type
Academic Supplement Monograph
Information
CNS Spectrums , Volume 4 , supplement S3: The Third International Obsessive-Compulsive Disorder Conference , May 1999, pp. 46 - 50
Copyright
Copyright © Cambridge University Press 1999

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

REFERENCES

1.Goodman, WK, Price, LH, Rasmussen, SA, Delgado, PL, Heninger, GR, Charney, DS. Efficacy of fluvoxamine in obsessive compulsive disorder. Arch Gen Psychiatry. 1989;46:36–44.CrossRefGoogle ScholarPubMed
2.Perse, TL, Greist, JH, Jefferson, JW, Rosenfeld, JW, Dar, R. Fluvoxamine treatment of obsessive compulsive disorder. Am J Psychiatry. 1987;144:1543–1548.Google ScholarPubMed
3.Cottraux, J, Mollard, E, Bouvard, M, et al.A controlled study of fluvoxamine and exposure in obsessive compulsive disorders. Int Clin Psychopharmacol. 1990;5:17–30.CrossRefGoogle Scholar
4.Goodman, WK. Fluvoxamine in the treatment of obsessive compulsive disorder. In: Montgomery, SA, Goodman, WK, eds. Current Approaches, Obsessive Compulsive Disorder. London, England: Duphar Medical Relations; 1994:64–73.Google Scholar
5.Greist, JH, Jenike, MA, Robinson, DS, Rasmussen, SA. Efficacy of fluvoxamine in obsessive-compulsive disorder: results of a multicentre, double blind, placebo-controlled trial. Eur J Clin Res. 1995;7:195–204.Google Scholar
6.Montgomery, SA, McIntyre, A, Osterheider, M, et al.A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive compulsive disorder. Eur Neuropsychopharmacol. 1993;3:143–152.CrossRefGoogle ScholarPubMed
7.Tollefson, GD, Rampey, AH, Potvin, JH, et al.A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1994;51:559–567.CrossRefGoogle ScholarPubMed
8.Chouinard, G. Sertraline in the treatment of obsessive compulsive disorders: two double-blind, placebo controlled studies. Int Clin Psychopharmacol. 1992;7S2:37–41.CrossRefGoogle Scholar
9.Greist, JH, Chouinard, G, DuBoff, E, et al.Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1995;52:289–295.CrossRefGoogle ScholarPubMed
10.Alderman, J, Wolkow, R, Chung, M, Johnston, HF. Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy. J Am Acad Child Adolesc Psychiatry. 1998;37:386–394.CrossRefGoogle ScholarPubMed
11.Wheadon, D, Bushnell, WD, Steiner, M. A fixed dose comparison of 20,40 or 60mg of paroxetine to placebo in the treatment of obsessive-compulsive disorder. 32nd Annual Congress of American College of Neuropsychopharmacology, December 1993. Abstract.Google Scholar
12.Zohar, J, Judge, R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry. 1996;69:468–474.CrossRefGoogle Scholar
13.Montgomery, SA. Citalopram treatment of obsessive compulsive disorder: results from a double-blind, placebo-controlled trial. 37th Annual Congress of American College of Neuropsychopharmacology, December 1998. Abstract.Google Scholar
14.Wood, A, Tollefson, GD, Birkett, M. Pharmacotherapy of obsessive compulsive disorder-experience with fluoxetine. Int Clin Psychopharmacol. 1993;8:301–306.CrossRefGoogle ScholarPubMed
15.Pigott, TA, Pato, M, Bernstein, SE, et al.Controlled comparison of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1990;47:926–932.CrossRefGoogle ScholarPubMed
16.Lopez-Ibor, JJ, Saiz, J, Cottraux, J, et al.Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. Eur Neuropsychopharmacol. 1996;6:111–118.CrossRefGoogle ScholarPubMed
17.Freeman, CP, Trimble, MR, Deakin, JFW, et al.Fluvoxamine or clomipramine in the treatment of obsessive-compulsive disorder? A multicenter, randomized double-blind, parallel group comparison. J Clin Psychiatry. 1994;55:301–305.Google ScholarPubMed
18.Koran, LM, McElroy, SL, Davidson, JRT, Rasmussen, SA, Hollander, E, Jenike, MA. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychiatry. 1996;16:121–129.Google ScholarPubMed
19.Milanfranchi, A, Ravagli, S, Lensi, P, Marazziti, D, Cassano, GB. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 1997;12:131–136.CrossRefGoogle ScholarPubMed
20.Smeraldi, E, Erzegovesi, S, Bianchi, I, et al.Fluvoxamine vs clomipramine treatment in obsessive-compulsive disorder: a preliminary study. New Trends Exp Clin Psychiatry. 1992;8:63–65.Google Scholar
21.Bisserbe, JC, Lane, RM, Flament, MF. A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder. Eur Psychiatry. 1997;12:82–93.CrossRefGoogle ScholarPubMed
22.Dunbar, GC, Steiner, M, Bushnell, WD. Long-term treatment and prevention of relapse of obsessive compulsive disorder with paroxetine. Eur Neuropsychopharmacol. 1995;5:372. Abstract.CrossRefGoogle Scholar
23.Greist, JH, Jefferson, JW, Kobak, KA, et al.A 1-year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 1995;10:57–65.CrossRefGoogle Scholar
24.Tollefson, GD, Birkett, M, Koran, LM, Genduso, LA. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. J Clin Psychiatry. 1994;55:69–76.Google ScholarPubMed
25.Hiss, H, Foa, E, Kozak, MJ. Relapse prevention program for treatment of obsessive-compulsive disorder. J Consult Clin Psychol. 1994;62:801–808.CrossRefGoogle ScholarPubMed
26.Lindsay, M, Crino, R, Andrews, G. Controlled trial of exposure and response prevention in obsessive-compulsive disorder. Br J Psychiatry. 1997;171:135–139.CrossRefGoogle ScholarPubMed
27.van Balkom, AJLM, de Haan, E, van Oppen, P, Spinhoven, P, Hoogduin, KAL, Van Dyck, R. Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder. J Nerv Mental Dis. 1998;186:494–499.CrossRefGoogle ScholarPubMed
28.Black, DW, Monahan, P, Gable, J, Blum, N, Clancy, G, Baker, P. Hoarding and treatment response in 38 nondepressed subjects with obsessive-compulsive disorder. J Clin Psychiatry. 1998;59:420–425.CrossRefGoogle ScholarPubMed
29.Marks, IM, Stern, RS, Mawson, D, Cobb, J, McDonald, R. Clomipramine and exposure for obsessive compulsive rituals. Br J Psychiatry. 1980;136:1–25.CrossRefGoogle ScholarPubMed
30.Hohagen, F, Winkelmann, G, Rasche-Rauchle, H, et al.Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Br J Psychiatry. 1998;173:71–78.CrossRefGoogle Scholar
31.Hollander, E, Stein, DJ, Kwon, JH, et al.Psychosocial function and economic costs of obsessive-compulsive disorder. CNS Spectrums. 1998;3:48–58.CrossRefGoogle Scholar
32.McDougle, CJ, Goodman, WK, Leckman, JF, Lee, NC, Heninger, GR, Price, LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 1994;51:302–306.CrossRefGoogle ScholarPubMed
33.McDougle, CJ, Fleischmann, RL, Epperson, CN, Wasyling, S, Leckman, JF, Price, LH. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry. 1995;56:526–528.Google ScholarPubMed
34.McDougle, CJ, Barr, LC, Goodman, WK, et al.Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry. 1995;152:1812–1814.Google ScholarPubMed